Canaccord Genuity Analysts Give Agios Pharmaceuticals Inc (AGIO) a $90.00 Price Target
Agios Pharmaceuticals Inc (NASDAQ:AGIO) received a $90.00 target price from research analysts at Canaccord Genuity in a report released on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price target points to a potential upside of 73.24% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 18th. Janney Montgomery Scott raised shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $57.00 price target for the company in a research note on Thursday, February 16th. Cann reissued a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research note on Wednesday, April 19th. Credit Suisse Group AG reissued an “outperform” rating and issued a $61.00 price target on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Finally, Oppenheimer Holdings Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 16th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $63.34.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 5.37% during mid-day trading on Thursday, hitting $49.16. 489,130 shares of the company traded hands. Agios Pharmaceuticals has a one year low of $35.84 and a one year high of $67.74. The firm has a 50 day moving average of $51.72 and a 200 day moving average of $50.44. The firm’s market capitalization is $2.37 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.24. The business had revenue of $10.51 million for the quarter, compared to analyst estimates of $9.65 million. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. Agios Pharmaceuticals’s revenue was down 66.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.64) EPS. Equities research analysts expect that Agios Pharmaceuticals will post ($6.44) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/05/19/canaccord-genuity-analysts-give-agios-pharmaceuticals-inc-agio-a-90-00-price-target.html.
In other Agios Pharmaceuticals news, insider Scott Biller sold 6,438 shares of the stock in a transaction on Monday, March 20th. The shares were sold at an average price of $55.00, for a total transaction of $354,090.00. Following the completion of the sale, the insider now owns 21,403 shares of the company’s stock, valued at approximately $1,177,165. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $53.11, for a total transaction of $108,131.96. Following the sale, the director now directly owns 94,769 shares of the company’s stock, valued at approximately $5,033,181.59. The disclosure for this sale can be found here. Insiders sold a total of 442,791 shares of company stock valued at $22,047,508 in the last ninety days. 10.55% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System boosted its stake in shares of Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the last quarter. Bank of Montreal Can raised its position in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the period. OMERS ADMINISTRATION Corp raised its position in shares of Agios Pharmaceuticals by 8.0% in the third quarter. OMERS ADMINISTRATION Corp now owns 5,400 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 400 shares during the period. Nationwide Fund Advisors raised its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock valued at $590,000 after buying an additional 500 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Agios Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares during the period. 88.79% of the stock is owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.